Physician profile
Mohammad J Mukhtar
NPI 1437258134
$1,736.31
in general payments reported to CMS, 2019-2025
22 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $158 · 2021: $16.76 · 2022: $39.55 · 2023: $278 · 2024: $271 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $455.69 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $240.81 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $193.27 | 2019-2025 | Ozempic |
| Amarin Pharma, INC. | $182.76 | 2019-2020 | |
| Astellas Pharma US INC | $101.74 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $66.53 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $55.81 | 2022-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $54.42 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $51.75 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.81 | 2019 | |
| Abbvie INC. | $49.27 | 2019-2021 | |
| Shield Therapeutics INC | $43.47 | 2023 | Accrufer |
| Allergan, INC. | $32.40 | 2019 | |
| Abbott Laboratories | $24.17 | 2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $19.84 | 2023 | Trelegy Ellipta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $19.31 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.92 | 2019 | |
| Seqirus USA INC | $16.58 | 2020 | |
| Phadia US INC. | $16.36 | 2023 | Immunocap |
| Lilly USA, LLC | $15.89 | 2024 | Mounjaro |
| Circassia INC. | $13.76 | 2019 | |
| Merck Sharp & Dohme LLC | $13.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Mukhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.